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ABSTRACT
Integrative oncology focuses on the roles of comple-
mentary therapies to increase the effectiveness of con-
ventional cancer treatment programs by improving
defined outcomes such as symptom control, quality of
life, rehabilitation, and prevention of recurrence. Imple-
mentation of integrative oncology programs should be
based on the best evidence and must continually be
evaluated to ensure quality, optimization of techniques,
collection of new data, and cost-effectiveness. Useful
domains that can be evaluated include symptom con-
trol, adherence to treatment protocols, quality of life,
individual outcomes, prevention, rehabilitation, poten-
tial advantages of a whole-systems health approach,
and economics of health services.
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1. INTRODUCTION
Integrative oncology focuses on the roles of comple-
mentary therapies such as meditation and other mind–
body approaches, music therapy, massage and other
touch therapies, acupuncture, natural health products
(botanicals, for example), nutrition, fitness therapies,
and more. Its goal is to increase the effectiveness of
conventional cancer treatment programs, to reduce
symptoms, and to improve quality of life for cancer
patients. The Consortium of Academic Health Cen-
ters for Integrative Medicine defines integrative medi-
cine as “the practice of medicine that reaffirms the
importance of the relationship between practitioner and
patient, focuses on the whole person, is informed by
evidence, and makes use of all appropriate therapeutic
approaches, healthcare professionals and disciplines
to achieve optimal health and healing.”
2. IMPLEMENTING INTEGRATIVE ONCOLOGY
Implementation of integrative oncology programs
should be based on the best evidence and must
continually be evaluated to ensure quality, optimization
How do we evaluate
outcome in an integrative
oncology program?
S.M. Sagar MD
of techniques, collection of new data, and cost-effec-
tiveness. Useful domains that can be evaluated include
symptom control, adherence to treatment protocols,
quality of life, individual outcomes, prevention, reha-
bilitation, potential advantages of a whole-systems
health approach, and economics of health services.
2.1 Symptom Control
Various modalities play a role in symptom control.
These include mind–body therapies (meditation, group
support, cognitive behavioural therapy, spirituality, yoga,
tai chi, qi gong, labyrinth walking), manipulative and
physical therapies (massage, acupuncture), biofield
therapies (polarity, healing touch, Reiki), natural health
products (botanicals), nutrition interventions
(phytoceuticals, diet adjustment), and ethnic health
systems (Traditional Chinese Medicine, Ayurveda,
Native American Medicine) 1. Current evidence for
safety and effectiveness has been summarized by the
Society for Integrative Oncology 2. Visual analogue
scales are often used to measure such symptoms as
pain, anxiety, and tension at baseline and after treat-
ment. Validated assessment procedures are required
to select and triage specific patients to an appropriate
therapy program.
An integrative medicine program provides oppor-
tunities to connect with the patient, enhance trust, and
communicate information in a supportive environment.
These factors increase adherence to treatment protocols
and can improve treatment response and survival 3,4.
Positive expectation, appreciation of meaning, and a
sense of optimism should be enhanced within the con-
text of factual knowledge 5,6.
A National Health System report from the United
Kingdom encourages positive expectation in the deliv-
ery of health care. A pessimistic approach can en-
courage the nocebo effect, which can result in poor
coping skills, disempowerment, and adverse health
outcomes 7. The aim of the report was to assess the
nature and extent of the placebo effect and to con-
sider how it may be harnessed within the National
Health System to improve the quality of care. The au-
thors concluded that the existing evidence justifies the
use of strategies to enhance expectancies—specifically,SAGAR
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to enhance accurate expectations by the patients about
medical procedures and how to cope with them. In
addition, evidence encourages the use of the positive
effects of expectation to enhance the skills of patients
for self-management of their illness, to improve com-
munication concerning health issues with health care
providers, and to enhance belief in the benefits of ef-
fective medical treatments.
2.2 Patient-Focused Approach
Patients that choose complementary or alternative
therapies require guidance. Such guidance is often not
available in cancer treatment organizations because
many of the staff are not trained in integrative oncol-
ogy and because information resources have not been
critically examined by a qualified person for credibil-
ity. Cancer “guide,” “navigator,” or “pathfinder” is
an important role for an appropriately trained health
care professional. Although many patients are simply
seeking empowerment and trying to do everything pos-
sible, some patients have important psychosocial is-
sues that need to be diagnosed and managed
appropriately. These issues can include cultural be-
liefs, heightened anxiety, fear, anger, advanced and
uncontrolled symptom burden, poor satisfaction with
conventional medicine, communication breakdown,
and misinformation that includes bogus therapies found
on the Internet 8,9.
The evaluation of integrative health care models
is becoming increasingly important, and an appropri-
ate set of outcome measures is required. Dr. Marja
Verhoef has proposed these questions 10:
• How do we identify the manner in which cancer
patients phrase and frame the beneficial outcomes
of their experience?
• What are the recommendations that can be made
for an appropriate outcome measures package to
evaluate integrative health care?
Through interviews and focus groups, Verhoef iden-
tified six types of benefit: physical well-being, change
in physiologic indicators, improved emotional well-
being, personal transformation, feelings of connected-
ness, global state of well-being, and cure. Patients’ goals
included improvement in their state of being, freedom
from cancer, increased energy, more effective pain
management, and achievement of an improved quality
of life.
The evaluation of medical practice should use quan-
titative and qualitative techniques alike. Contemporary
medicine is assumed to be conceptually based on mod-
ern science; however, the summation of quantity and
quality is impossible to evaluate using only scientific
parameters. Integrative medicine is postulated to be
comprehensive in its fundamental doctrine, emphasiz-
ing a holistic approach, including technical, artistic,
social, religious, philosophic, and ethical elements. The
personal preferences of patients for outcome as defined
by qualitative experiences is emphasized. The World
Health Organization suggests that health be evaluated
from the viewpoint of the disability-adjusted life ex-
pectancy, which is expressed using both quantity (life
expectancy) and quality of life. One of the challenges
of assessing the utility of integrative oncology is the
expression of joint measurements of quantitative and
qualitative outcomes. Medical quantity and quality are
in reality mixed and fused together, both in treatment
and in outcomes.
2.2.1 Quantitative Evaluation of an Intervention for an
Individual
The N-of-1 randomized controlled trial was designed
to evaluate the contribution to the therapeutic process
of an intervention as compared with either a placebo
(expectation) effect or regression to the mean. The
patient participates in choosing the intervention. Dis-
tinguishing the components of healing is probably not
an important issue if the intervention is safe and inex-
pensive. It may not be applicable to the cancer patient
when conditions change rapidly. In addition, the re-
sources and expenses of implementing this type of
evaluation must be taken into account. That being said,
the N-of-1 trial may have a place in the evaluation of
some treatment programs 11,12.
2.2.2 Qualitative Evaluation of an Intervention for an
Individual
A major benefit of integrative therapies is their poten-
tial to improve quality of life (QOL). Evaluation of QOL
is now a standard of clinical investigation that is rou-
tinely used in addition to measurement of tumour re-
sponse. An improvement in symptom control, coping,
and function enhances rehabilitation and restoration of
a normal lifestyle. Nevertheless, an understanding of
what QOL is and how it should be evaluated is a very
difficult matter.
A fundamental part of the definition of a high QOL
is a large degree of freedom in thinking and behaviour
that includes personal subjective feelings. As a result,
the cornerstones of science—which include objectiv-
ity, universality, reproducibility, and logical consis-
tency—can no longer be totally applied. Evaluation of
medical practices in terms of QOL is non-scientific in
this respect, because those scientific characteristics
are not preserved 13. The fact that so many QOL evalu-
ation parameters have been proposed ultimately sug-
gests that none are reliable. Unless a logical and
scientific way of assessing personal feelings is estab-
lished, QOL simply cannot be evaluated using scien-
tific analysis and numeric expression.
Because QOL may vary between individuals ac-
cording to their primary problems and values, individual
and personalized QOL criteria may be more appropri-
ate for measuring outcomes. The Measure Yourself
Medical Outcome Profile was developed to allow
patients to set their own criteria for QOL outcomes.EVALUATING OUTCOME IN AN INTEGRATIVE ONCOLOGY PROGRAM
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This measure was developed further for cancer pa-
tients in the form of the validated Measure Yourself
Concerns and Wellbeing assessment protocol, which
specifically evaluates outcome in cancer supportive
care that includes complementary therapies 14,15
(Table I).
The term ‘‘healing enhancement’’ (Mayo Clinic,
Rochester, MN, U.S.A.) was coined to identify the
goals of an emerging paradigm that focuses on all
aspects of the patient’s experience—mind, body, and
spirit 16. That subjective experience of healing was
investigated in a multi-method pilot study 17: Before
and after each of 6 weekly healing sessions, percep-
tion of well-being and client experience were assessed
in 15 clients by the EuroQol, the Measure Yourself Con-
cerns and Wellbeing index, and a client satisfaction
tool. Qualitative methods included focus groups that
explored the perceived effects of healing in more depth.
Over the course of healing, quantitative data showed
perceived significant improvements in concerns or
problems for which clients wanted help and in distress-
ing symptoms of anxiety and depression. Qualitative
analysis showed that clients sought help mainly for psy-
chological and emotional concerns. Clients attributed
many of the quantitative improvements to healing it-
self. The study suggested that clients and healers per-
ceive healing to have a range of benefits, particularly
in terms of coping with cancer.
Research to date indicates that patients who are
involved in their own care and who take an active role
in their treatment feel better and have an improved
recovery. Other studies have shown that depression
predicts cancer incidence or progression, although not
all studies agree. Rosenbaum et al. 18 discussed this
effect in more detail. A randomized study that com-
pared QOL according to the survival of patients in the
adjuvant and metastatic settings noted that an increase
in QOL included improved mood, appetite, and well-
being, and hence facilitated longer survival 19. That
finding suggests that QOL may also play a role in de-
termining a patient’s length of life. Resources and pro-
grams that are shown to improve QOL, such as the
Stanford Cancer Supportive Care Program, promote a
more meaningful and longer lifespan for those strug-
gling with cancer.
Because QOL involves subjective measurement in
domains such as the psychological, functional, and so-
cial, it can be difficult to assess. Unlike readily quan-
tifiable measures, such as weight or tumour size, QOL
is not as easily defined. Interpretation of QOL differs
with each person and is influenced by factors such as
culture, age, and life experience. The patient evalua-
tions from the Stanford Cancer Supportive Care Pro-
gram suggest that participants received several
benefits from the programs, such as an increase in
sense of well-being, reduced feelings of stress, an
increase in energy, more restful sleep, and an increase
in hopefulness and empowerment—all ingredients that
improve QOL 18.
2.3 Systems Approach to Health Care
Integrative oncology recognizes a systems approach
to health care. A program of coordinated appropriate
interventions may be more effective than individual
therapies. The holistic approach to health is a matur-
ing tautology that is now binding the sciences from mo-
lecular biology to psychosocial and health services
research 20. Systems approaches, by taking the myriad
of connections into account, are more suited for ad-
dressing chronic, long-term improvements. In many
chronic diseases, the body system may not have been
healthy over a prolonged period of time before the
symptoms appeared.
Only short-term improvements can be obtained by
aiming at a particular subsystem related to the symp-
toms. Overall sustained improvement can be obtained
only through multiple interventions. A multi-pronged
approach encourages homeostasis to return to the whole
physiologic organism. For example, diabetes care in-
volves the interaction of nutrition, exercise, stress
management, and education—not just the prescription
of insulin. Instead of disease management, health pro-
motion becomes the aim of the intervention.
Whole-systems research explores effectiveness
through observational studies that combine qualitative
TABLE I Measure Yourself Concerns and Wellbeing assessment form a
Concern or problem 1: 0123456
Not bothering me Bothers me
at all        greatly
How would you rate your general feeling of well being now? 0123456
As good        As bad
as it can be as it can be
Other things affecting your health; changes you have made yourself
What has been most important to you?
a  Available at www.bristol.ac.uk/hsrc/research/other/mymop/index.html (registration required).SAGAR
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and quantitative approaches such as pattern of interac-
tions, context, process, philosophy, and outcomes. It
deals with “real life” scenarios and recognizes mul-
tiple inseparable components, model validity, effec-
tiveness, and external validity 21,22. A systems analysis
can reveal new approaches to improve the current situ-
ation of ever-increasing health care costs.
2.4 Health Economics
The financial implications of integrative oncology pro-
grams require evaluation with respect to functional
outcomes, in-kind contributions, safety, restoration of
function, and efficiency of rehabilitation 23. The self-
empowerment of individuals using complementary
therapies can have life-long advantages for self–health
care. Short-term measurements of outcome may not
reflect lifetime benefits 24. Using complementary
therapies over the long term, together with judicious tem-
porary pharmacologic therapies, could have cost-effec-
tiveness advantages. For example, short-term
administration of antidepressant drugs may give the pa-
tient adequate function to learn cognitive behavioural
techniques that will become the source of a maintenance
regimen after withdrawal of the pharmaceuticals.
Measuring QOL with respect to financial cost is
methodologically challenging. Quality-adjusted life
year (QALY) is a quantitative measurement that may
allow for a financial comparison between various in-
terventions and their related health outcomes. The main
problem is to be able to compare “apples with oranges”
(to use a common expression). The ability to compare
directly the dollar cost of various health outcomes is
attractive to the decision-maker. However, the use of
the QALY for this purpose has severe limitations, and
these limitations must be widely understood 25. A key
question is who is to make the subjective choices that
determine the QALY? Is it health professionals? The
general public? Or patients who have experience of
the particular medical condition and treatment? Other
problems include the hypothetical nature of the situa-
tions being responded to, which therefore may not ac-
curately reflect real human decisions, and the influence
that the length of the illness and the way in which the
questions are asked influence the valuations made. Fi-
nally, QALYs are likely to undervalue health care be-
cause they do not capture the wider benefits.
The evidence for cost advantages of complemen-
tary therapies is limited because the research is at an
early stage 26,27. Many outcomes studies are not well
controlled, and determining whether outcome is attrib-
utable to the intervention, expectation, regression to
the mean, or a combination of these factors is diffi-
cult. This difficulty has led to much controversy and
many unwarranted claims 28,29. However, uncertain
evidence of effectiveness does not necessarily preclude
a positive recommendation in a guideline, and original
modelling of cost-effectiveness can be part of guide-
line development 30.
3. CHALLENGES
Integrating complementary therapies into conventional
cancer care poses a number of challenges. What is
required is an integration of the best approaches to can-
cer care with a more cohesive move forward based on
collaboration and open-mindedness. Skepticism comes
from lack of knowledge and training, and the result is
a reluctance to refer patients to CAM therapists 31.
However, implementation of an evidence-based inte-
grative medicine program within an academic setting
can be successful. A survey of one large academic in-
stitution with a Chair for Holistic and Integrative Medi-
cine (Wake Forest University Baptist Medical Center,
Winston–Salem, NC, U.S.A.) concluded that strong
interest is present among medical staff. Future studies
will need to assess the cost-effectiveness of such ser-
vices, their financial sustainability, and their effect on
patient satisfaction, health, and quality of life 32.
Most mainstream and complementary medicine
practitioners agree that patients should take an active
role in their care, that an understanding of treatment
and its goals should be established between the patient
and practitioners, and that the culture should encourage
patients to take responsibility for their health 33. We need
to focus on the “effectiveness gaps” in the treatment of
cancer patients. For example, emesis, fatigue, neuropa-
thy, anxiety, insomnia, and cachexia are some symp-
toms that continue to show problematic responses to
conventional therapies. Drawing together services and
developing expertise in integrative health care requires
leadership to promote team-building. However, without
collaboration and support, such visions are limited. With-
out audit and evaluation of outcomes, they will not be
TABLE II Champion ideas for CAM and cancer care (adapted from Mackereth and Stringer, 2005 34)
Encourage researchers to be sensitive to the vulnerabilities of people affected by cancer and mindful of their values and concerns.
Collaborate with cancer interest groups, education and communication specialists, researchers, other national and international programs.
Provide leadership training and support to assist practitioner innovation, to build dynamic services, and to disseminate their work.
Improve information and access to CAM therapies within public cancer services.
Provide greater equity in funding service provision and research.
Involve users, with the goal of providing cost-effective, accountable, and responsive services.
Ensure safety of therapies and credentialing of practitioners.EVALUATING OUTCOME IN AN INTEGRATIVE ONCOLOGY PROGRAM
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accepted by mainstream practitioners. Championing in-
tegrative oncology focuses on the value of the vision
and the public acknowledgment of that value. A willing-
ness to measure and act upon the results of clinical out-
comes studies is more important than are policies based
on outdated cynicism (Table II) 34.
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